Aprea Therapeutics Announces Submission of IND Application for APR-1051, a Next Generation WEE1 Kinase Inhibitor
Aprea Therapeutics, Inc. has submitted an Investigational New Drug (IND) application to the FDA for APR-1051, an oral inhibitor of WEE1 kinase. The company believes APR-1051 is potentially differentiated from other WEE1 inhibitors and has demonstrated highly potent anti-tumor activity in pre-clinical studies. Pending FDA clearance, Aprea plans to commence clinical testing in the first half of 2024.
Positive
Submission of IND application is an important milestone for APR-1051 development program
APR-1051 has potentially superior pharmacokinetic properties
Extensive pre-clinical studies have demonstrated highly potent anti-tumor activity of APR-1051
From an oncological perspective, the submission of an IND for APR-1051 by Aprea Therapeutics is a critical step towards addressing unmet needs in precision oncology. WEE1 kinase, an important regulator in cell cycle control and DNA damage response, is a promising target due to its role in cancer cell proliferation. APR-1051's claimed selectivity and pharmacokinetic advantages could translate into better efficacy and reduced side effects compared to existing therapies. The focus on patients with specific genetic or molecular signatures aligns with the current trend towards personalized medicine, potentially improving outcomes for subgroups of patients who may not respond to more generalized treatments.
As a medical research analyst, the transition of APR-1051 from preclinical to clinical stages signifies a substantial investment into its development pipeline. Aprea's emphasis on the molecule's unique structure and selectivity suggests a strategic positioning to capture a niche in the competitive landscape of WEE1 inhibitors. The pharmacokinetic profile, if as favorable as suggested, could mean a more convenient dosing regimen and better patient adherence. The upcoming Phase 1/2a trials will be crucial for investors to watch, as they will provide initial data on safety and efficacy that will inform the drug's future potential and impact on Aprea's valuation.
In terms of market dynamics, Aprea Therapeutics' announcement may stir investor interest due to the potential of APR-1051 to become a 'best in class' therapy. The precision oncology market is rapidly growing, with an increasing demand for targeted treatments. If APR-1051 proves to be superior to other WEE1 inhibitors, it could capture significant market share and drive revenue growth for Aprea. However, the long road to regulatory approval and the risks inherent in clinical trials should be considered by stakeholders. The biopharmaceutical sector is highly volatile and the success of clinical trials is a key determinant of a company's financial health and stock performance.
02/06/2024 - 08:01 AM
DOYLESTOWN, Pa., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food & Drug Administration (FDA) to initiate clinical trials of APR-1051. APR-1051 is an oral inhibitor of WEE1 kinase, which plays important role in cell cycle regulation and DNA damage repair.
Based on preclinical studies, we believe APR-1051 is potentially differentiated from other WEE1 inhibitors in its: 1) molecular structure; 2) selectivity for WEE1 versus off-target inhibition of the polo-like kinase, or PLK, family of kinases; and 3) potentially superior pharmacokinetic properties.* Aprea has conducted extensive pre-clinical studies with APR-1051, which have demonstrated that the molecule may have highly potent anti-tumor activity, with a potentially favorable pharmacokinetic (PK) profile.
“Submission of an IND represents an important milestone for our APR-1051 development program,” said Dr. Oren Gilad, President and CEO of Aprea. “APR-1051 is a next generation inhibitor of WEE1 kinase and, based on its unique characteristics, we believe it will be best in class. Pending clearance of the IND by FDA, we plan to commence clinical testing in the first half of 2024.”
Clearance of the IND application will allow Aprea to initiate a Phase 1/2a dose escalation trial to evaluate the safety, tolerability, and preliminary efficacy of APR-1051 as a monotherapy in patients with a defined genetic and/or molecular signatures. Further details on the design of this study will be provided at a later date.
* No head-to-head studies have been conducted with APR-1051
About Aprea www.aprea.com .
The Company may use, and intends to use, its investor relations website at https://ir.aprea.com/ as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD.
Forward-Looking Statement Certain information contained in this press release includes “forward-looking statements”, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended related to our study analyses, clinical trials, regulatory submissions, and projected cash position. We may, in some cases use terms such as “future,” “predicts,” “believes,” “potential,” “continue,” “anticipates,” “estimates,” “expects,” “plans,” “intends,” “targeting,” “confidence,” “may,” “could,” “might,” “likely,” “will,” “should” or other words that convey uncertainty of the future events or outcomes to identify these forward-looking statements. Our forward-looking statements are based on current beliefs and expectations of our management team and on information currently available to management that involve risks, potential changes in circumstances, assumptions, and uncertainties. All statements contained in this press release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize, and achieve market acceptance of our current and planned products and services, our research and development efforts, including timing considerations and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations. Any or all of the forward-looking statements may turn out to be wrong or be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. These forward-looking statements are subject to risks and uncertainties including, without limitation, risks related to the success, timing, and cost of our ongoing clinical trials and anticipated clinical trials for our current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including our ability to fully fund our disclosed clinical trials, which assumes no material changes to our currently projected expenses), futility analyses, presentations at conferences and data reported in an abstract, and receipt of interim or preliminary results (including, without limitation, any preclinical results or data), which are not necessarily indicative of the final results of our ongoing clinical trials, our ability to continue as a going concern, our understanding of product candidates mechanisms of action and interpretation of preclinical and early clinical results from its clinical development programs, and the other risks, uncertainties, and other factors described under “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents we file with the U.S. Securities and Exchange Commission. For all these reasons, actual results and developments could be materially different from those expressed in or implied by our forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which are made only as of the date of this press release. We undertake no obligation to update such forward-looking statements for any reason, except as required by law.
Investor Contact:
Mike Moyermmoyer@lifesciadvisors.com
Aprea Therapeutics, Inc. submitted an IND application to the FDA for APR-1051, an oral inhibitor of WEE1 kinase.
APR-1051 is an oral inhibitor of WEE1 kinase.
Aprea plans to commence clinical testing for APR-1051 in the first half of 2024, pending FDA clearance.
Extensive pre-clinical studies have demonstrated highly potent anti-tumor activity of APR-1051.
